<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 14 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple><div class=WordSection1><p class=MsoNormal>Date: July 29, 2014<o:p></o:p></p><p class=MsoNormal>Time 2.00 P.M<o:p></o:p></p><p class=MsoNormal style='margin-bottom:12.0pt'>Venue: ECE Conference Room<o:p></o:p></p><p class=MsoNormal>Committee chair: Dr Ben Jansen<o:p></o:p></p><p class=MsoNormal style='margin-bottom:12.0pt'>Committee members: Dr Haluk Ogmen, Dr Merrill Hiscock, Dr Christian Schaaf.<o:p></o:p></p><div><div><div><p class=MsoNormal align=center style='text-align:center'><a name="OLE_LINK8"></a><a name="OLE_LINK9"></a><a name="OLE_LINK10"></a><a name="OLE_LINK11"></a><a name="OLE_LINK12"><b><span style='font-size:14.0pt'>Sensory Gating Analysis in Individuals with Copy Number Variants of <i>CHRNA7</i><o:p></o:p></span></b></a></p><p class=MsoNormal align=center style='text-align:center'><b><span style='font-size:14.0pt'>Hamza Kagalwala<o:p></o:p></span></b></p><p class=MsoNormal align=center style='text-align:center'><b><span style='font-size:14.0pt'>Abstract<o:p></o:p></span></b></p><p class=MsoNormal style='text-align:justify;line-height:200%'> Sensory gating, the brain’s ability to suppress irrelevant stimuli, was studied in 15 subjects with CHRNA7 gene deletions, 16 with gene duplications, and 28 of their siblings. <o:p></o:p></p><p class=MsoNormal style='text-align:justify;line-height:200%'> Pairs of brief tones were repeatedly presented and the brain’s responses to the first (S1) and second (S2) tone in each pair were recorded during baseline in all subjects, and after administration of a placebo and actual medication, respectively in the gene abnormality groups. The amplitude, latency and area under the curve were measured for the P50, N100 and P200 component. <o:p></o:p></p><p class=MsoNormal style='text-align:justify;line-height:200%'> Siblings had smaller P200 amplitudes for S1 than patients, but no gating differences were observed. The P50 amplitude for S2 was smaller after medication than at baseline, and the corresponding gating ratio approached significance. <o:p></o:p></p><p class=MsoNormal style='text-align:justify;line-height:200%'> In conclusion, subjects with CHRNA7 gene abnormalities and their siblings have similar gating ratios, but medication tends to reduce the P50 gating deficit.<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p></div></div></div></div></body></html>